|
[1]
|
Razavi-Shearer, D., Gamkrelidze, I., Nguyen, M.H., Chen, D., Van Damme, P., Abbas, Z., et al. (2018) Global Prevalence, Treatment, and Prevention of Hepatitis B Virus Infection in 2016: A Modelling Study. The Lancet Gastroenterology & Hepatology, 3, 383-403. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Su, S., Wong, W.C., Zou, Z., Cheng, D.D., Ong, J.J., Chan, P., et al. (2022) Cost-Effectiveness of Universal Screening for Chronic Hepatitis B Virus Infection in China: An Economic Evaluation. The Lancet Global Health, 10, e278-e287. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Bertoletti, A. and Le Bert, N. (2018) Immunotherapy for Chronic Hepatitis B Virus Infection. Gut and Liver, 12, 497-507.
|
|
[4]
|
Coffin, C.S., Zhou, K. and Terrault, N.A. (2019) New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology, 156, 355-368.e3.
|
|
[5]
|
Wang, Y., Yang, S., Su, C., Wang, Y., Lee, K., Huo, T., et al. (2016) Predictors of Response to Pegylated Interferon in Chronic Hepatitis B: A Real-World Hospital-Based Analysis. Scientific Reports, 6, Article No. 29605. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Yeh, M.L., Huang, J.F., Dai, C.Y., et al. (2019) Pharmacokinetics and Pharmacodynamics of Pegylated Interferon for the Treatment of Hepatitis B. Expert Opinion on Drug Metabolism & Toxicology, 15, 779-785.
|
|
[7]
|
Villar, L.M., Cruz, H.M., Barbosa, J.R., Bezerra, C.S., Portilho, M.M. and Scalioni, L.d.P. (2015) Update on Hepatitis B and C Virus Diagnosis. World Journal of Virology, 4, 323-342. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
World Health Organization (2017) WHO Guidelines on Hepatitis B and C Testing.
http://www.ncbi.nlm.nih.gov/books/NBK442272/
|
|
[9]
|
European Association for the Study of the Liver (2017) Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398.
|
|
[10]
|
Terrault, N.A., Lok, A.S.F., McMahon, B.J., Chang, K., Hwang, J.P., Jonas, M.M., et al. (2018) Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67, 1560-1599. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Xie, Z., Zhu, S., Peng, Y., Chen, J., Wang, X., Ma, L., et al. (2015) Postoperative Hepatitis B Virus Reactivation and Surgery-Induced Immunosuppression in Patients with Hepatitis B-Related Hepatocellular Carcinoma: PHR and Immunosuppression in HCC Patients. Journal of Surgical Oncology, 112, 634-642. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Park, J.W. (2015) Differentiation of Acute and Chronic Hepatitis B in IgM Anti-HBc Positive Patients. World Journal of Gastroenterology, 21, 3953-3959. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Tabor, E., Hoofnagle, J.H., Barker, L.F., Pineda-Tamondong, G., Nath, N., Smallwood, L.A., et al. (1981) Antibody to Hepatitis B Core Antigen in Blood Donors with a History of Hepatitis. Transfusion, 21, 366-371. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Vanwolleghem, T., et al. (2021) Humoral Immunity in Hepatitis B Virus Infection: Rehabilitating the B in HBV. JHEP Reports, 4, Article ID: 100398.
https://pubmed.ncbi.nlm.nih.gov/35059620/
|
|
[15]
|
Jeng, W., Papatheodoridis, G.V. and Lok, A.S.F. (2023) Hepatitis B. The Lancet, 401, 1039-1052. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Dini, G., Toletone, A., Barberis, I., Debarbieri, N., Massa, E., Paganino, C., et al. (2016) Persistence of Protective Anti-HBs Antibody Levels and Anamnestic Response to HBV Booster Vaccination: A Cross-Sectional Study among Healthcare Students 20 Years Following the Universal Immunization Campaign in Italy. Human Vaccines & Immunotherapeutics, 13, 440-444. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Li, Q., Ren, X., Lu, C., Li, W., Huang, Y. and Chen, L. (2017) Evaluation of APRI and FIB-4 for Noninvasive Assessment of Significant Fibrosis and Cirrhosis in HBeAg-Negative CHB Patients with ALT ≤ 2 ULN: A Retrospective Cohort Study. Medicine, 96, e6336. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Xiao, G., Yang, J. and Yan, L. (2014) Comparison of Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Adult Patients with Chronic Hepatitis B Virus Infection: A Systemic Review and Meta-Analysis. Hepatology, 61, 292-302. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Wu, S., Liu, L., Cheng, J., Liu, Y., Cheng, L., Wang, S., et al. (2018) Longitudinal Monitoring of Liver Fibrosis Status by Transient Elastography in Chronic Hepatitis B Patients during Long-Term Entecavir Treatment. Clinical and Experimental Medicine, 18, 433-443. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Bâldea, V., Bende, F., Popescu, A., Șirli, R. and Sporea, I. (2021) Comparative Study between Two 2d-Shear Waves Elastography Techniques for the Non-Invasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C Virus (HCV) Infection. Medical Ultrasonography, 23, 257-264. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Huang, D., Lin, T., Wang, S., et al. (2019) The Liver Fibrosis Index Is Superior to the APRI and FIB-4 for Predicting Liver Fibrosis in Chronic Hepatitis B Patients in China. BMC Infectious Diseases, 19, Article No. 878.
|
|
[22]
|
Malagnino, V., Fofana, D.B., Lacombe, K. and Gozlan, J. (2018) Occult Hepatitis B Virus Infection: An Old Entity with Novel Clinical Involvements. Open Forum Infectious Diseases, 5, ofy227. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Pawlotsky, J.M., Dusheiko, G., Hatzakis, A., et al. (2008) Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. Gastroenterology, 134, 405-415.
|
|
[24]
|
Mangia, A., Antonucci, F., Brunetto, M., Capobianchi, M., Fagiuoli, S., Guido, M., et al. (2008) The Use of Molecular Assays in the Management of Viral Hepatitis. Digestive and Liver Disease, 40, 395-404. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Chen, R.W., Piiparinen, H., Seppänen, M., Koskela, P., Sarna, S. and Lappalainen, M. (2001) Real-Time PCR for Detection and Quantitation of Hepatitis B Virus DNA: Real-Time PCR for HBV DNA. Journal of Medical Virology, 65, 250-256. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Chen, H., Sun, L., Zheng, H., Zhang, Q. and Jin, X. (2012) Total Serum DNA and DNA Integrity: Diagnostic Value in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Pathology, 44, 318-324. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T., Kitis, G., Rizzetto, M., et al. (2006) Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology, 131, 1743-1751. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Kumar, R., Pérez-Del-Pulgar, S., Testoni, B., et al. (2016) Clinical Relevance of the Study of Hepatitis B Virus Covalently Closed Circular DNA. Liver International, 36, 72-77.
|
|
[29]
|
Werle-Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., et al. (2004) Persistence of cccDNA during the Natural History of Chronic Hepatitis B and Decline during Adefovir Dipivoxil Therapy. Gastroenterology, 126, 1750-1758.
|
|
[30]
|
Al-Sadeq, D.W., Taleb, S.A., Zaied, R.E., et al. (2019) Hepatitis B Virus Molecular Epidemiology, Host-Virus Interaction, Coinfection, and Laboratory Diagnosis in the MENA Region: An Update. Pathogens (Basel, Switzerland), 8, 63.
|
|
[31]
|
Fletcher, G.J., Eapen, C.E. and Abraham, P. (2019) Hepatitis B Genotyping: The Utility for the Clinicians. Indian Journal of Gastroenterology, 39, 315-320. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Wang, J., Zhang, P., Zeng, J., Du, P., Zheng, X., Ye, X., et al. (2020) Occurrence of Occult Hepatitis B Virus Infection Associated with Envelope Protein Mutations According to Anti-HBs Carriage in Blood Donors. International Journal of Infectious Diseases, 92, 38-45. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Wong, G.L.H., Chan, H.L.Y., Yiu, K.K.L., et al. (2013) Meta-Analysis: The Association of Hepatitis B Virus Genotypes and Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics, 37, 517-526. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Van Campenhout, M.J.H., Van Bömmel, F., Pfefferkorn, M., et al. (2018) Host and Viral Factors Associated with Serum Hepatitis B Virus RNA Levels among Patients in Need for Treatment. Hepatology (Baltimore, Md.), 68, 839-847.
|
|
[35]
|
Giersch, K., Allweiss, L., Volz, T., Dandri, M. and Lütgehetmann, M. (2017) Serum HBV pgRNA as a Clinical Marker for Cccdna Activity. Journal of Hepatology, 66, 460-462. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Xu, L., Li, X., Lu, L., Liu, X., Song, X., Li, Y., et al. (2022) HBV pgRNA Profiles in Chinese HIV/HBV Coinfected Patients under Pre-and Post-Treatment: A Multicentre Observational Cohort Study. Journal of Viral Hepatitis, 29, 616-626. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Wang, J., Shen, T., Huang, X., Kumar, G.R., Chen, X., Zeng, Z., et al. (2016) Serum Hepatitis B Virus RNA Is Encapsidated Pregenome RNA That May Be Associated with Persistence of Viral Infection and Rebound. Journal of Hepatology, 65, 700-710. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Ji, X., Xia, M., Zhou, B., Liu, S., Liao, G., Cai, S., et al. (2020) Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog. Infection and Drug Resistance, 13, 1881-1888. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Ye, J. and Chen, J. (2021) Interferon and Hepatitis B: Current and Future Perspectives. Frontiers in Immunology, 12, Article ID: 733364.
|
|
[40]
|
Marcellin, P., Xie, Q., Woon Paik, S., et al. (2020) Final Analysis of the International Observational S-Collate Study of Peginterferon Alfa-2a in Patients with Chronic Hepatitis B. PLOS ONE, 15, e0230893.
|
|
[41]
|
Tan, G., Song, H., Xu, F., et al. (2018) When Hepatitis B Virus Meets Interferons. Frontiers in Microbiology, 9, Article No. 1611.
|
|
[42]
|
Lebossé, F., Testoni, B., Fresquet, J., et al. (2017) Intrahepatic Innate Immune Response Pathways Are Downregulated in Untreated Chronic Hepatitis B. Journal of Hepatology, 66, 897-909.
|
|
[43]
|
Li, G.J., Yu, Y.Q., Chen, S.L., et al. (2015) Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment. Antimicrobial Agents and Chemotherapy, 59, 4121-4128.
|
|
[44]
|
Brideau-Andersen, A.D., Huang, X., Sun, S.C., Chen, T.T., Stark, D., Sas, I.J., et al. (2007) Directed Evolution of Gene-Shuffled IFN-α Molecules with Activity Profiles Tailored for Treatment of Chronic Viral Diseases. Proceedings of the National Academy of Sciences, 104, 8269-8274. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Bahardoust, M., Mokhtare, M., Barati, M., Bagheri-Hosseinabadi, Z., Karimi Behnagh, A., Keyvani, H., et al. (2020) A Randomized Controlled Trial of Pegylated Interferon-Alpha with Tenofovir Disoproxil Fumarate for Hepatitis B E Antigen-Negative Chronic Hepatitis B: A 48-Week Follow-Up Study. Journal of Infection and Chemotherapy, 26, 1265-1271. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Ning, Q., Han, M., Sun, Y., Jiang, J., Tan, D., Hou, J., et al. (2014) Switching from Entecavir to PegIFN Alfa-2a in Patients with Hbeag-Positive Chronic Hepatitis B: A Randomised Open-Label Trial (OSST Trial). Journal of Hepatology, 61, 777-784. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Lok, A.S.F., Mcmahon, B.J., Brown, R.S., et al. (2016) Antiviral Therapy for Chronic Hepatitis B Viral Infection in Adults: A Systematic Review and Meta-Analysis. Hepatology (Baltimore, Md.), 63, 284-306.
|
|
[48]
|
Manzoor, S., Saalim, M., Imran, M., et al. (2015) Hepatitis B Virus Therapy: What’s the Future Holding for Us? World Journal of Gastroenterology, 21, 12558-12575.
|
|
[49]
|
Thompson, A.J.V., Ayres, A., Yuen, L., Bartholomeusz, A., Bowden, D.S., Iser, D.M., et al. (2006) Lamivudine Resistance in Patients with Chronic Hepatitis B: Role of Clinical and Virological Factors. Journal of Gastroenterology and Hepatology, 22, 1078-1085. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Ho, E.Y., Yau, T., Rousseau, F., Heathcote, E.J. and Lau, G.K.K. (2015) Preemptive Adefovir versus Lamivudine for Prevention of Hepatitis B Reactivation in Chronic Hepatitis B Patients Undergoing Chemotherapy. Hepatology International, 9, 224-230. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Agarwal, K., Fung, S.K., Nguyen, T.T., Cheng, W., Sicard, E., Ryder, S.D., et al. (2015) Twenty-Eight Day Safety, Antiviral Activity, and Pharmacokinetics of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B Infection. Journal of Hepatology, 62, 533-540. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Su, T., Hu, T., Chen, C., Huang, Y., Chuang, W., Lin, C., et al. (2016) Four-Year Entecavir Therapy Reduces Hepatocellular Carcinoma, Cirrhotic Events and Mortality in Chronic Hepatitis B Patients. Liver International, 36, 1755-1764. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Wooddell, C.I., Gehring, A.J., Yuen, M.F., et al. (2021) RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses, 13, 581.
|
|
[54]
|
Yuen, M.F., Schiefke, I., Yoon, J.H., et al. (2020) RNA Interference Therapy with ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients with Chronic Hepatitis B Infection. Hepatology, 72, 19-31.
|
|
[55]
|
Yuen, M.F., Gane, E.J., Kim, D.J., et al. (2019) Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology, 156, 1392-1403.e7.
|
|
[56]
|
Zoulim, F., Lenz, O., Vandenbossche, J.J., Talloen, W., Verbinnen, T., Moscalu, I., et al. (2020) JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection. Gastroenterology, 159, 521-533.e9. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Hu, J. and Liu, K. (2017) Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses, 9, 56.
|
|
[58]
|
Bazinet, M., Pântea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., et al. (2020) Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. Gastroenterology, 158, 2180-2194. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Bazinet, M., Pântea, V., Cebotarescu, V., Cojuhari, L., Jimbei, P., Albrecht, J., et al. (2017) Safety and Efficacy of REP 2139 and Pegylated Interferon Alfa-2a for Treatment-Naive Patients with Chronic Hepatitis B Virus and Hepatitis D Virus Co-Infection (REP 301 and REP 301-LTF): A Non-Randomised, Open-Label, Phase 2 Trial. The Lancet Gastroenterology & Hepatology, 2, 877-889. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Ruiz de Galarreta, M. and Lujambio, A. (2017) Therapeutic Editing of Hepatocyte Genome in Vivo. Journal of Hepatology, 67, 818-828. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Liu, X., Hao, R., Chen, S., Guo, D. and Chen, Y. (2015) Inhibition of Hepatitis B Virus by the Crispr/cas9 System via Targeting the Conserved Regions of the Viral Genome. Journal of General Virology, 96, 2252-2261. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Hong, X., Kim, E.S. and Guo, H. (2017) Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B. Hepatology (Baltimore, Md.), 66, 2066-2077.
|
|
[63]
|
Krebs, K., Böttinger, N., Huang, L.R., et al. (2013) T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice. Gastroenterology, 145, 456-465.
|
|
[64]
|
Gehring, A.J., Xue, S.A., Ho, Z.Z., et al. (2011) Engineering Virus-Specific T Cells That Target HBV Infected Hepatocytes and Hepatocellular Carcinoma Cell Lines. Journal of Hepatology, 55, 103-110.
|
|
[65]
|
Janssen, H.L.A., Brunetto, M.R., Kim, Y.J., et al. (2018) Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally Suppressed Patients with Chronic Hepatitis B. Journal of Hepatology, 68, 431-440.
|